ImmunoACT
The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.
Overview
ImmunoACT was established in 2018 as a spin-off from IIT Bombay, where Rahul Purwar's group had worked on a humanised CD19 CAR since 2013. Clinical development ran with Tata Memorial Centre: first patients were dosed at Tata Memorial Hospital in 2021 and the DCGI granted market authorisation for NexCAR19 (talicabtagene autoleucel) in 2023, India's first approved CAR-T therapy. The phase 1/2 study (64 enrolled at six centres) reported an overall response rate of 73% in 51 evaluable patients. The company reports more than 600 patients treated across over 130 authorised centres, a 98% manufacturing success rate, about 20 days from apheresis to infusion and a WHO-certified GMP facility with capacity for 750 patients a year, expanding to 1,500. It received a US patent in 2025 and in 2026 partnered with Cipla to supply South Africa, Algeria and Morocco.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +1
Pages like this
not linked directly; found by shared links- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
- ProductVarnimcabtagene autoleucel
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, CD19, Manufacturing cost and time for living and radioactive medicines.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, CD19, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Prices and value, Acute lymphoblastic leukaemia.
- TrialIMAGINE (varnimcabtagene autoleucel, Immuneel)
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, Acute lymphoblastic leukaemia.
- CompanyCellogen Therapeutics
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- IdeaIn vivo CAR-T manufactured and priced like a generic biologic
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Prices and value, Most of the world has almost no cancer care.
- IdeaHospital-based CAR-T manufacturing at cost through a public network
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Prices and value, Acute lymphoblastic leukaemia.